Pharnext
Agnes Daoust has a diverse work experience in the field of clinical operations. Agnes began their career at UCB Pharma in 2005 as a Senior Clinical Project Manager. Agnes then moved on to Aepodia France in 2009, where they held the position of SN Outsourcing Manager & Clinical Project Leader. Since 2015, Agnes Daoust has been working at Pharnext, initially as a Clinical Project Leader and currently serving as the Director of Clinical Operations.
Agnes Daoust holds a PhD in Toxicology from Pierre and Marie Curie University. The specific start and end years of their education are not provided.
This person is not in any offices
Pharnext
Pharnext esPharnext is an advanced, clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.